BridgeBio Oncology Therapeutics logo
BridgeBio Oncology Therapeutics
BBOT | NASDAQ
Chart Builder DCF Calculator
$1.98
-$0.16 (-7.48%)
At close: Nov 16, 2026, 4:00 PM ET
$2.01
+$0.03 (+1.52%)
After-hours: Nov 16, 2026, 7:00 PM ET

BridgeBio Oncology Therapeutics Company Profile

Company profile explained

Company Profile

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the United States. The company develops BBO-8520, an orally bioavailable small molecule direct inhibitor, which is in Phase I clinical trial for the treatment of patients with KRASG12C mutant non-small cell lung cancer; and BBO-11818, an orally bioavailable small molecule pan-KRAS inhibitor, which is in Phase I clinical trial for the treatment of patients with KRAS G12D and KRAS G12V cell-derived xenograft models. It is also involved in the development of BBO-10203, an orally bioavailable small molecule, which is in Phase I clinical trial for the treatment of patients with HER2+ breast cancer, HR+/HER2- breast cancer, KRAS mutant colorectal cancer, and KRAS mutant non-small cell lung cancer; and precision oncology assets for patients with tumors. The company was incorporated in 2016 is headquartered in South San Francisco, California.

Key Executives

Name Position
Pedro J. Beltran Chief Executive Officer and Director
Idan Elmelech Chief Operating Officer
Aaron Chan Vice President of Legal
Bin Wang Senior Vice President of Drug Discovery
Daniel Watson Senior Vice President of Chemistry, Manufacturing & Controls
Frank McCormick Co-Founder, Non-Executive Director & Chair of the Advisory Board
Marc Cobo VP of Finance & Controller
Neil Kumar Executive Chairman
Rui Xu Senior Vice President of Drug Discovery
Yong Ben Chief Medical & Development Officer

Latest SEC Filings

Date Type Title
Oct 23, 2026 4 Filing
Oct 05, 2026 4 Filing
Oct 05, 2026 4 Filing
Oct 05, 2026 4 Filing
Oct 05, 2026 4 Filing
Sep 14, 2026 4 Filing
Sep 10, 2026 EFFECT Filing
Sep 08, 2026 EFFECT Filing
Sep 08, 2026 8-K Current Report
Sep 01, 2026 S-3 Filing
View All SEC Filings ➞
BridgeBio Oncology Therapeutics
BridgeBio Oncology Therapeutics logo
Country United States
IPO Date Aug 12, 2025
Industry Biotechnology
Sector Healthcare
Employees 88
CEO Pedro J. Beltran

Contact Details

256 E. Grand Avenue South San Francisco, California 94080 United States

Stock Details

Ticker Symbol BBOT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001869105
CUSIP Number 107924102
ISIN Number US1079241022
SIC Code 6770

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.